Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Novartis Expands Biosimilar Portfolio

The Swiss-based pharma giant looks to compensate for expired patents on blockbuster drugs by doubling down on biosimilars.

Novartis / Photo: forbes.com
Novartis / Photo: forbes.com

A Forbes article dated July 19th looked at Novartis’ aggressive plans for the biosimilar market. Expired patents and a commitment to providing low-cost treatments to rare and life-threatening diseases has resulted in lost revenue for the Swiss-based company, but they plan to more than make up for it with their generics division, Sandoz.

By the end of 2016, Sandoz plans to submit 11 biosimilar molecules for FDA approval, including several generic versions of mega-blockbusters. Some noteworthy drugs include “Enbrel by Amgen and Pfizer, Humira by AbbVie, Neulasta by Amgen, Remicade by Johnson & Johnson and Merck, and Rituxan by Roche,” according to the article.

The R&D process for biosimilars is much more technical than generics, costing between $40 million and $300 million to develop a drug in just five years. Sandoz plans to spend $1 billion over the next 10 years to expand their R&D facility in Austria, a small sum compared to the $44 billion generated in 2015 by the five aforementioned brand name drugs.

Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?